glp-1 timeline History of glucagon-like peptide-1 receptor agonists The transformative breakthroughs in GLP-1

They are not approved for human use by the FDA outside of clinical trials

It's a silent variable that can invalidate an entire study

This Special Feature discusses the challenges associated with assessing changes in muscle mass that accompany GLP-1 drug-induced weight loss, the potential impact of muscle mass loss, and how to preserve muscle mass

VAT is the deep fat compartment that surrounds abdominal organs, elevates cardiovascular and metabolic risk markers, and tends to be resistant to diet and exercise interventions that reduce subcutaneous fat

Defining recovery in chronic fatigue syndrome: a critical review

results are obtained in minutes with high repeatability and this method is able to detect small fiber loss in prediabetes and recently diagnosed T2D [49]